Treatment of chronic hepatitis B infection

500 mcg daily; 1000 mcg daily in lamivudine-refractory patients

Molecular weight :295.3

%Protein binding :13

%Excreted unchanged in urine : 75

Volume of distribution (L/kg) :Large

half-life – normal/ESRD (hrs) :128–149

30–50 250 mcg daily; 500 mcg daily in lamivudine-refractory patients10–30 150 mcg daily; 300 mcg daily in lamivudine-refractory patients

<10 : 50 mcg daily; 100 mcg daily in lamivudine-refractory patients

CAPD :0.3% dialysed. Dose as in GFR <10 mL/min

HD :13% dialysed. Dose as in GFR <10 mL/min

HDF/high flux :Dialysed. Dose as in GFR

<10 : mL/min

CAV/VVHD :Likely to be dialysed. Dose as in GFR=10–30 mL/min

Potentially hazardous interactions with other drugs

None known

–

Oral

–

–